The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Praxis Precision Medicines Inc. (PRAX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.06, or 4.55%, to $1.38. The Praxis Precision Medicines Inc. has recorded 15,937 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference.
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $1.32 and fluctuated between $1.3700 as its day high and $1.3000 as its day low. The current market capitalization of Praxis Precision Medicines Inc. is $175.78M. A total of 0.6 million shares were traded on the day, compared to an average of 1.16M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, PRAX has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 10,000 and the disposition of 0 shares. Over the last 12 months, there were 11 BUYs and 7 SELLs from insiders. Insiders purchased 175,860 shares during that period but sold 9,100.
In the most recent transaction, Souza Marcio bought 10,000 shares of PRAX for 1.06 per share on Jun 27. After the transaction, the Chief Executive Officer now owns 45,002 company shares. In a previous transaction on Mar 24, MITCHELL DEAN J bought 50,000 shares at 0.84 per share. PRAX shares that Director owns now total 75,000.
Among the insiders who bought shares, Souza Marcio acquired of 35,002 shares on Mar 23 at a per-share price of $0.86. This resulted in the Chief Executive Officer holding 35,002 shares of PRAX after the transaction. In another insider transaction, Souza Marcio bought 35,000 shares at $0.86 per share on Mar 23. Company shares held by the Chief Executive Officer now total 226,299.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for PRAX in the last 3 months, the mean price target is $7.75 with high estimates of $18.00 and low estimates of $2.00. In terms of 52-week highs and lows, PRAX has a high of $5.25 and a low of $0.79.
As of this writing, PRAX has an earnings estimate of $Virax Biolabs Group Limited per share for the current quarter. EPS was calculated based on a consensus of Praxis Precision Medicines, Inc estimates, with a high estimate of $PRA Group, Inc. per share and a lower estimate of $PainReform Ltd.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. PRAX’s latest balance sheet shows that the firm has $275.91M in Cash & Short Term Investments as of fiscal 2021. There were $4.31M in debt and $37.62M in liabilities at the time. Its Book Value Per Share was $1.51, while its Total Shareholder’s Equity was $250.81M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for PRAX is Buy with a score of 4.33.